Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MEDI1814 for · 1 trial · 2 indications
Tolerability measured by participant withdrawal for an adverse event from randomization through end of study
| Arm | Type | Description |
|---|---|---|
| MEDI1814 IV | EXPERIMENTAL | Upto 10 cohorts of subjects are planned to be dosed by IV injection, with single and multiple ascending doses ranging from 25-1800mg. |
| IV Placebo | PLACEBO_COMPARATOR | Upto 10 cohorts of subjects are planned to be dosed by IV injection, with single and multiple ascending doses ranging from 25-1800mg. |
| MEDI1814 Sub Cutaneous Injection | EXPERIMENTAL | 2 cohorts of subjects are planned to be dosed by sub cutaneous injection, one single ascending dose and one multiple ascending dose cohort |
| Subcutaneous Placebo | PLACEBO_COMPARATOR | 2 cohorts of subjects are planned to be dosed by sub cutaneous injection, one single ascending dose and one multiple ascending dose cohort |
| Name | Type | Description |
|---|---|---|
| MEDI1814 for IV injection | BIOLOGICAL | Monoclonal antibody for IV Injection |
| MEDI1814 for Subcutaneous Injection | BIOLOGICAL | Monoclonal antibody for subcutaneous injection |
| IV Placebo | BIOLOGICAL | Placebo for IV injection |
| Placebo for Subcutaneous Injection | BIOLOGICAL | Subcutaneous Placebo Injection |
Inclusion Criteria Male and female (non child bearing potential) subjects Mild-moderate Alzheimer's Disease Exclusion Criteria History or evidence of significant autoimmune disease Presence of psychiatric disorder which would affect completion of the study Current serious or unstable clinically imp...
MEDI1814 is an investigational monoclonal antibody being studied for the treatment of mild to moderate Alzheimer's disease. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities. The drug is being evaluated for its safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with this condition.
MEDI1814 is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker AZN. The company is conducting clinical research to evaluate the drug's potential in treating mild to moderate Alzheimer's disease.
MEDI1814 is in Phase 1 clinical development. A Phase 1 study has been completed, which assessed the safety, tolerability, pharmacokinetics, and pharmacodynamics of the drug in subjects with mild to moderate Alzheimer's disease. The drug remains investigational and is not yet approved for clinical use.
MEDI1814 has one completed clinical trial registered under NCT02036645. This Phase 1 study was a single ascending dose and multiple ascending dose trial that evaluated the drug's safety, tolerability, pharmacokinetics, and pharmacodynamics in subjects with mild to moderate Alzheimer's disease and healthy elderly individuals.
Yes, the completed Phase 1 trial for MEDI1814 was a randomized, double-blind, placebo-controlled study. The trial enrolled 77 participants in the United States, with a minimum age of 55 years. The study included both male and female subjects and did not enroll healthy volunteers.